Logo

Voluntis' Oleena Digital Application Receives FDA's Marketing Approval to Self-Manage Cancer Symptoms

Share this

Voluntis' Oleena Digital Application Receives FDA's Marketing Approval to Self-Manage Cancer Symptoms

Shots:

  • The US FDA has completed its regulatory review of Oleena software which is a Class II medical device facilitating oncology-related symptoms management and remote patient monitoring
  • Oleena is embedded with clinical algorithms offerings real-time personalized insights and actionable recommendations to the patients for managing their own symptoms while monitoring remote patients will improve clinical outcomes and minimizes the burden on health systems
  • Voluntis’ Oleena is the first prescription digital therapeutic in oncology transforming the patient’s experience through their cancer journey and is based on a software platform- Theraxium Oncology which is designed to allow data analytics and remote maintenance of digital therapeutics

Click here to­ read full press release/ article | Ref: Voluntis | Image: Digital Health London


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions